NLS Pharmaceutics priced a USD 20 million IPO of 4,819,277 units consisting of one common share and one warrant to purchase one common share which are immediately separable from the units and issued separately.
The common shares and the warrants have been approved for listing on the Nasdaq Capital Market under the symbols “NLSP” and “NLSPW”, respectively, and trading began on January 29, 2021. The offering closed on February 2, 2021.
Lenz & Staehelin acted as Swiss counsel to the underwriters. The team included Patrick Schleiffer, Patrick Schärli and Ann Francesca Weibel (all Corporate and Capital Markets).
Headquarted in Stans, Switzerland, NLS Pharmaceutics is a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders.